The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease

被引:52
作者
Zietkowski, Z [1 ]
Kucharewicz, I [1 ]
Bodzenta-Lukaszyk, A [1 ]
机构
[1] Med Univ Bialystok, Dept Allergol & Inbternal Dis, PL-15276 Bialystok, Poland
关键词
chronic obstructive; pulmonary disease; exhaled nitric oxide; inhaled corticosteroids; smoking;
D O I
10.1016/j.rmed.2004.12.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the study was to evaluate the exhaled nitric oxide (F-ENO) in clinically stable chronic obstructive pulmonary disease (COPD), its relationship to the severity of the disease, pulmonary function, smoking status, reversibitity of airflow limitation, and ICS therapy. The study was conducted in 47 patients with COPD and 40 healthy controls. Flow/ volume spirometry and FENO measurement were performed before and after 2 months of ICS therapy. F-ENO were significantly elevated in current smokers and ex-smoking COPD patients. In both groups of COPD patients inhaled corticosteroids (ICS) therapy caused a significant decrease in FENO without significant changes in FEV1. A positive correlation between initial F-ENO and postbronchoditator FEV1 (% predicted) was observed in the group of ex-smoking COPD patients, but not in the currently smoking COPD group. In both groups of COPD patients, the initial level of F-ENO correlated with the reversibitity of airway obstruction, the increase in postbronchodilator FEV1, and the decrease in F-ENO following ICS treatment. F-ENO increases in patients with stable COPD. ICS therapy decreased elevated F-ENO levels in these patients without statistically significant changes in lung function. The selection of COPD patients with increased F-ENO level and partial reversibility of airway obstruction should be helpful in terms of proposed ICS treatment. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:816 / 824
页数:9
相关论文
共 30 条
[21]  
RENGASAMY A, 1993, MOL PHARMACOL, V44, P124
[22]   Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease [J].
Senderovitz, T ;
Vestbo, J ;
Frandsen, J ;
Maltbæk, N ;
Norgaard, M ;
Nielsen, C ;
Kampmann, JP .
RESPIRATORY MEDICINE, 1999, 93 (10) :715-718
[23]   OPTIMAL ASSESSMENT AND MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE (COPD) [J].
SIAFAKAS, NM ;
VERMEIRE, P ;
PRIDE, NB ;
PAOLETTI, P ;
GIBSON, J ;
HOWARD, P ;
YERNAULT, JC ;
DECRAMER, M ;
HIGENBOTTAM, T ;
POSTMA, DS ;
REES, J .
EUROPEAN RESPIRATORY JOURNAL, 1995, 8 (08) :1398-1420
[24]   Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients [J].
Silkoff, PE ;
McClean, P ;
Spino, M ;
Erlich, L ;
Slutsky, AS ;
Zamel, N .
CHEST, 2001, 119 (05) :1322-1328
[25]   Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease [J].
Sin, DD ;
Lacy, P ;
York, E ;
Man, SFP .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (07) :760-765
[26]  
Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104
[27]   Exhaled nitric oxide in COPD: glancing through a smoke screen [J].
Sterk, PJ ;
de Gouw, HWFM ;
Ricciardolo, FLM ;
Rabe, KF .
THORAX, 1999, 54 (07) :565-567
[28]   Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease [J].
Szafranski, W ;
Cukier, A ;
Ramirez, A ;
Menga, G ;
Sansores, R ;
Nahabedian, S ;
Peterson, S ;
Olsson, H .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (01) :74-81
[29]   EFFECT OF SMOKING CESSATION ON AIRWAY INFLAMMATION IN CHRONIC-BRONCHITIS [J].
TURATO, G ;
DISTEFANO, A ;
MAESTRELLI, P ;
MAPP, CE ;
RUGGIERI, MP ;
ROGGERI, A ;
FABBRI, LM ;
SAETTA, M .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (04) :1262-1267
[30]  
VAN RE, 1999, THORAX, V54, P403